A user's progress in treating their hair loss with Finasteride, Minoxidil and Dermarolling; they discussed details of their routine and others congratulated them on their success.
The conversation discusses using GFM Gel, a topical gel with polypeptides that mimic growth factors to promote hair regrowth and strengthen hair. It also mentions treatments like Minoxidil, finasteride, and RU58841 for hair loss.
PP405 shows potential for hair growth by increasing terminal hair and converting vellus hairs, but results are modest and more waiting is needed. It complements existing treatments like minoxidil and finasteride, but won't replace them.
The user is considering switching from pyrilutamide to 0.025% topical finasteride due to concerns about effectiveness and past side effects from a scalp elixir. They aim to maintain hair until new treatments like breezula or GT00029 become available.
The user shared their 5-month hair regrowth progress using oral finasteride daily, topical minoxidil twice daily, derma stamping weekly, castor oil weekly, and the Nioxin system kit. Replies praised the results and inquired about the timeline and side effects.
A 25-year-old is starting finasteride to address hair loss, having previously used minoxidil and other treatments. Users discuss experiences with finasteride, including initial shedding and side effects, while offering advice and support.
A Swiss product called Redensyl, which is supposed to target hair follicle stem cells and has recently been marketed in Europe. The post inquires if anyone has had any experience with the product.
Glycine supplementation may increase 5-alpha reductase activity, potentially affecting hair loss. Users discuss its impact on hair fall and its role in the body.
Over 5 years, the user saw hair improvement using finasteride and dermarolling, but experienced hair loss with weightlifting. Recently increased finasteride dose and is more careful with dermarolling, but is not considering minoxidil.
A 26-year-old individual treating hair loss since 19, using a regimen of Finasteride, Cyproterone, Oral Minoxidil, Microneedling, Dutasteride, and newly added RU58841. They're seeking advice from other RU58841 users about their experiences.
A Phase 1 update for the HMI 115 clinical trial, which involves 16 participants and is expected to end in July 2023; as well as changes to the recruitment process, including treatment protocols with Minoxidil, Finasteride, and RU58841.
The conversation discusses concerns about brain fog potentially caused by finasteride use, with some users sharing personal experiences of cognitive issues and others suggesting it might be paranoia or unrelated. The original poster decides to stop using finasteride to see if their cognitive function improves.
The user is considering adding RU58841 to their current hair loss treatment of finasteride and minoxidil, but is concerned about potential side effects like hairline recession and shedding. Some users report positive results with RU58841, while others experience side effects such as chest pain and dizziness.
RU58841, an anti-androgenic compound, showed early promise for treating alopecia but faced challenges after its patent in 1997. Despite advancing to Phase II trials, safety concerns and financial struggles led Aventis to abandon its development. Proskelia, which later merged into ProStrakan, couldn't prioritize the drug, leading to its eventual stagnation and failure to reach the market.
Finasteride's impact on fertility is discussed, with users sharing experiences of conceiving while on the medication. Concerns about long-term safety are also mentioned.
A 20-year-old user experienced significant hair regrowth after using 5% minoxidil foam and finasteride for four months, starting to see results after two months with no side effects. They also cut off damaged hair ends, wash their hair every other day, and advise managing stress to improve hair loss outcomes.
PP405 shows promising results for hair growth, potentially outperforming finasteride without side effects like erectile dysfunction. Users discuss using treatments like minoxidil, pyrilutamide, nizoral, and alfatradiol while waiting for PP405's availability.
Follicopeptide (FOL005) by Coegin Pharma will launch as a cosmetic hair growth treatment by Q2 2025, showing similar efficacy to finasteride. Users discuss the benefits and skepticism of releasing hair loss treatments as cosmetics rather than drugs.
The conversation is about obtaining a finasteride prescription through Lemon Aid Health. The user is exploring the process and alternatives for getting the prescription sent to a pharmacy.
The conversation discusses the application of RU58841 for hair loss, with the user applying 1.75 mg at 5% concentration for half an hour daily. The user mentions managing seborrheic dermatitis while using this treatment.
The user shared five months of progress using oral finasteride, topical minoxidil, and supplements like biotin, zinc, omega-3, and collagen. They noted encouraging results, while others suggested trying oral minoxidil or microneedling for potentially better outcomes.
The user is concerned about starting finasteride due to ongoing body development and seeks alternatives to maintain hair until age 25. They are considering options other than finasteride for hair loss management.
The conversation is about a product called FLEAVA, found in a Facebook ad, and whether it is effective or just another scam. One user believes it is likely a scam and mentions that such products usually don't compete with Minoxidil.
The user is seeking help with using Ell-Cranell for hair loss treatment. They are unsure about the correct application method and dosage. They also inquire about combining microneedling with topical alfatradiol and question a study that referred to alfatradiol as a hair growth inhibitor in male mice.
The relative strength of Pyrilutamide compared to RU58841 in terms of androgen receptor binding affinity. It has been noted that Pyrilutamide is 4x stronger than RU58841, with a higher binding affinity than DHT itself.
OP is using 0.5mg dutasteride, 5mg biotin, 5% topical minoxidil twice daily, and dermarolling 1-2 times a week for hair loss. OP reports no side effects and is happy with the progress after 5 months.
A 23-year-old male has been using 0.25mg finasteride daily for 4.5 months to address early-stage male pattern baldness, with positive results and no significant side effects. He plans to continue with this dosage and may consider increasing it or adding minoxidil if necessary.